Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
NightHawk Biosciences (NYSE American: NHWK) has reported its strategic, financial, and operational updates for the year ended December 31, 2022. The company recognized $6.4 million in revenue, primarily from product sales of ANTHIM® to the Canadian government. However, it faced a net loss of $43.4 million, resulting in a loss per share of ($1.70). NightHawk is transitioning towards biodefense and biomanufacturing, investing in facilities in San Antonio and Kansas. As of December 31, 2022, it had $44.3 million in cash and equivalents, but an audit opinion raised concerns about its ability to continue as a going concern due to recurring losses.